Boston Scientific Corp (BSX) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Total Revenue Chart for Boston Scientific Corp
Boston Scientific Corp (BSX) revenue for FY2025 was USD 20.1B, a 19.9% change from FY2024. Boston Scientific Corp's revenue grew from USD 230.0M in 1991 to USD 20.1B in 2025 (8627.8% over 34 years). Earnings per share grew from USD 0.45 in 2000 to USD 1.94 in 2025 (326.2%). Revenue compound annual growth rate: 5-year CAGR of 15.2%, 10-year CAGR of 10.4%, 20-year CAGR of 6.0%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $61.87B
- Implied Share Price
- $42.69
- Enterprise Value
- $73.58B
- Revenue (TTM)
- $21.07B
- EBITDA
- $5.77B
- Profit Margin
- 16.62%
- Trailing P/E
- 18.01
- Forward P/E
- 12.58
- Price/Book (MRQ)
- 2.47
- Price/Sales (TTM)
- 2.94
- EV/EBITDA
- 14.84
- EV/Revenue
- 3.49
- Dividend Yield
- —
- Book Value
- $16.34
- Free Cash Flow (FY2025)
- $3.66B
- Free Cash Flow Yield
- 5.91%
Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.